ArticleFrontiers in oncology2025
Survival disparities and predictors in gastric cancer: a population-based study from Kazakhstan (2012-2023).
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology, outcomes of treatment, and survival of cervical cancer in Kazakhstan: a nationwide population-based study.Frontiers in oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gastric cancer remains a major global health burden, with Central Asia, Kazakhstan in particular, exhibiting high incidence and mortality. There is a lack of recent national data providing a detailed clinical picture of gastric cancer. Most reports have been limited to summary statistics on incidence or mortality, without stratification by tumor stage, histological subtype, survival, or associated comorbidities. This study addresses gaps by using national registry data to evaluate 12-year gastric cancer trends, patient characteristics, and outcomes. We aim to investigate gastric cancer epidemiology, survival, and associated risk factors in Kazakhstan for the prevention and control strategies. Methods: This retrospective cohort study analyzed 33,992 patients with gastric cancer using the Unified National Electronic Healthcare System in Kazakhstan from 2012 to 2023. Cases were identified via ICD-10 codes (C16.0-C16.9). Demographic, staging, histological, treatment and comorbidity data were extracted. Outcomes included incidence, mortality, and survival. Kaplan-Meier analysis and Cox regression were used to evaluate survival differences and predictors. Population-based rates were age-standardized using WHO standards. Results: The age-standardized incidence rate declined from 17.46 to 13.63 per 100,000; mortality dropped from 16.16 to 8.74. Prevalence doubled over 12 years. Most cases (33.5%) were diagnosed at Stage III, closely followed by Stage II and Stage IV. One- and five-year survival rates were 38.1% and 17.1%, respectively. Men and patients aged 60-69 had the highest incidence. Survival declined sharply with stage: Stage I (49.1%) vs Stage IV (3.5%, P < 0.001). The most common tumor site was the cardia, and adenocarcinoma was the predominant histology. Cox regression identified older age (HR 1.17 per decade), advanced stage (HR 3.48 for Stage IV), recurrence, metastases and cancer complications as significant mortality predictors (all P < 0.001). Cardiovascular and gastrointestinal diseases were the most common comorbidities. Conclusion: Gastric cancer in Kazakhstan shows late-stage diagnosis and poor survival. Targeted screening, earlier diagnosis, and improved management of comorbidities are essential to improve outcomes and reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.